[ATNM] Actinium Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: AMEX

The data is delayed by 15 minutes.

 

Price: 0.97 Change: -0 (-0.5%)
Ext. hours: Change: 0 (0%)

chart ATNM

Refresh chart

Strongest Trends Summary For ATNM

ATNM is in the medium-term down -18% in 2 months and down -62% in 1 year. In the long-term down -74% below S&P in 1 year and down -99% below S&P in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Actinium Pharmaceuticals, Inc., a biotechnology company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform. Its products include Bismab-A for acute myeloid leukemia; Actimab-A, an antibody-drug construct that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia; and Iomab-B, an antibody-drug construct used in myeloconditioning for hematopoietic stem cells transplantation in various indications. The company was formerly known as Cactus Ventures, Inc. and changed its name to Actinium Pharmaceuticals, Inc. in April 2013. Actinium Pharmaceuticals, Inc. was founded in 2000 and is based in New York, New York.

Fundamental Ratios
Shares Outstanding EPS-0.54 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-2.07
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-55.16% ROE-67.28% ROI
Current Ratio5.52 Quick Ratio Long Term Debt/Equity Debt Ratio0.22
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities18.39 M Cash From Investing Activities Cash From Operating Activities-5.81 M Gross Profit
Net Profit-3.07 M Operating Profit-7.87 M Total Assets20.06 M Total Current Assets19.92 M
Total Current Liabilities3.61 M Total Debt190 K Total Liabilities3.61 M Total Revenue
Technical Data
High 52 week0.82 Low 52 week0.2 Last close0.2 Last change-0.51%
RSI9.3 Average true range0.01 Beta1.17 Volume288.91 K
Simple moving average 20 days-9.47% Simple moving average 50 days-11.28% Simple moving average 200 days-48.79%
Performance Data
Performance Week-1.99% Performance Month-14.72% Performance Quart-14.35% Performance Half-60.84%
Performance Year-75.01% Performance Year-to-date-49.1% Volatility daily2.73% Volatility weekly6.11%
Volatility monthly12.52% Volatility yearly43.36% Relative Volume353.16% Average Volume632.42 K
New High New Low

News

2019-11-07 16:05:00 | Actinium Pharmaceuticals to Present at the 25th Annual BIO-Europe® 2019 International Partnering Conference

2019-11-06 09:15:00 | Actinium Announces Interim Results from Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML Accepted for Presentation at ASH 2019

2019-11-06 09:00:00 | Actinium Pharmaceuticals to Present New Clinical Findings from SIERRA Trial Supporting the Iomab-ACT Program for Targeted Lymphodepletion for CAR-T and Adoptive Cell Therapies at ASH 2019

2019-10-28 08:20:00 | Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment

2019-10-15 10:48:01 | What Kind Of Investor Owns Most Of Actinium Pharmaceuticals, Inc. NYSEMKT:ATNM?

2019-09-30 08:00:00 | Actinium Announces Participation at the 2019 Cell & Gene Meeting on the Mesa

2019-09-23 08:00:00 | Actinium Announces Iomab-B Poster Selected for Honorable Distinction Award at the 2019 Society of Hematologic Oncology Annual Meeting from Nearly Four Hundred Abstracts

2019-09-16 08:00:00 | Actinium Pharmaceuticals to Present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering & Investment

2019-07-23 08:00:00 | Actinium Achieves Fifty Percent Enrollment in the Pivotal Phase 3 SIERRA Trial for Iomab-B

2019-07-17 12:56:33 | How Actinium Pharmaceuticals, Inc. NYSEMKT:ATNM Can Impact Your Portfolio Volatility

2019-07-11 08:00:00 | Actinium Highlights Two Presentations at the Health Physics Society Annual Meeting Supporting the Safety Profile of Iomab-B for SIERRA Trial Caregivers

2019-06-26 08:00:00 | Actinium Poster Detailing Actinium-225 Labeled Daratumumab Selected in Top Poster Award Competition at 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting

2019-06-25 08:00:00 | Actinium Presents New Data Demonstrating Effective Lymphodepletion with Lutetium-177 for CAR-T at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting

2019-06-20 08:00:00 | Actinium's Portfolio of Antibody Radiation-Conjugates to be Highlighted in Two Oral and Two Poster Presentations at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting

2019-06-04 08:00:00 | Actinium Presents New Pivotal Phase 3 SIERRA Trial Data Showing Rapid Peripheral Blast Reduction and Anti-Leukemic Effect with Single Agent Iomab-B in Older Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia at 2019 ASCO Annual Meeting

2019-05-24 13:40:28 | Investors Who Bought Actinium Pharmaceuticals NYSEMKT:ATNM Shares Five Years Ago Are Now Down 98%

2019-05-16 08:00:00 | Abstract Highlighting New Data from the Iomab-B Pivotal Phase 3 SIERRA Trial to be Presented at 2019 ASCO Annual Meeting

2019-05-07 08:00:00 | Actinium Announces Appointment of Niva Almaula, Ph.D. as Chief Business Officer

2019-04-18 09:00:00 | Actinium Pharmaceuticals, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock and Warrants

2019-04-17 16:01:00 | Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants

2019-04-08 08:00:00 | Actinium's Leading Clinical, Preclinical, Production and IP Efforts Related to Actinium-225 Highlighted at Preeminent Targeted Alpha Therapy International Symposium

2019-04-04 09:57:01 | The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

2019-04-03 09:16:01 | Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy

2019-04-03 08:00:00 | Actinium Highlights Actimab-A and Venetoclax Synergies Observed in New Studies Presented at AACR

2019-04-01 09:00:01 | What Makes Actinium ATNM a New Buy Stock

2019-03-29 08:00:00 | Actinium Successfully Completes Second Module of Collaborative Research Program with Astellas; Third Module Initiated

2019-03-26 08:00:00 | Actinium Highlights its Participation at the Upcoming Targeted Alpha Therapy International Symposium with Presentations on its AWE Platform, Clinical Programs and New Source of Ac-225 Isotope

2019-03-20 08:00:00 | Actinium Announces Update Including IP and New Data from Novel Combination of Actimab-A and Venetoclax Accepted for Poster Presentation at AACR Annual Meeting

2019-03-19 17:05:00 | Actinium Appoints Accomplished FDA and Industry Professional Mamata Gokhale, Ph.D., RAC as Vice President, Global Head of Regulatory Affairs

2019-03-19 17:00:00 | Actinium Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Highlights

2019-03-15 17:05:00 | Actinium Provides Comprehensive Patent Portfolio Update Including New IP Filings

2019-03-15 08:00:00 | Actinium Pharmaceuticals to Present at the Oppenheimer & Co. 29th Annual Healthcare Conference

2019-03-07 12:15:09 | What Type Of Shareholder Owns Actinium Pharmaceuticals, Inc.’s NYSEMKT:ATNM?

2019-02-25 14:20:00 | 4 Healthcare Stocks Looking To Kick Off A Strong Week

2019-02-25 08:00:00 | Actinium's Late Breaking Oral Presentation at 2019 TCT Meetings Reports New Data on Donor Chimerism Indicating Deep Engraftment in All Iomab-B Treated Patients in the Pivotal Phase 3 SIERRA Trial

2019-02-21 08:00:00 | Actinium Highlights New Data at TCT Meetings Demonstrating Effective Lymphodepletion Supporting Iomab-ACT Program Development for Targeted Conditioning Prior to CAR-T and Adoptive Cell Therapy

2019-02-15 07:40:00 | Consolidated Research: 2019 Summary Expectations for Caesars Entertainment, Gol Linhas Aereas Inteligentes S.A, Zillow Group, Gladstone Land, Actinium Pharmaceuticals, and Kforce — Fundamental Analysis, Key Performance Indications

2019-02-12 08:00:00 | Iomab-B One of Four Late Breaking Oral Presentations to be Presented at the 2019 Transplantation & Cellular Therapy Annual Meeting

2019-02-06 08:00:00 | Actinium Provides Patent Portfolio Update for its Iomab-ACT Next-Generation CAR-T Lymphodepletion Program

2019-02-05 08:00:00 | Actinium Initiates Novel Phase 1/2 Combination Trial of Actimab-A and Venetoclax

2019-02-04 08:00:00 | Actinium Initiates Second Dosing Cohort of Novel Combination Trial with Actimab-A and CLAG-M Salvage Regimen at Medical College of Wisconsin

2019-01-29 08:00:00 | Actinium Pharmaceuticals to Host Key Opinion Leader Breakfast on Targeted Conditioning for Bone Marrow Transplant and CAR-T on February 7th

2019-01-25 08:00:00 | Actinium Pharmaceuticals, Inc. to Present at Noble Capital Markets' 15th Annual Investor Conference

2019-01-23 08:00:00 | Actinium Pharmaceuticals Appoints Accomplished Industry Executive Cynthia Pussinen as Executive Vice President of Technical Operations and Supply Chain

2019-01-17 08:00:00 | Actinium Successfully Completes First Module of Collaborative Research Program with Astellas; Second Module Initiated

2019-01-16 08:00:00 | Actinium Pharmaceuticals Appoints Qing Liang, PhD, DABR as Vice President, Head of Radiation Sciences to Further Innovation for its AWE Technology Platform and Growing Pipeline of Antibody Radiation Conjugate Therapies

2019-01-03 08:00:00 | Actinium Pharmaceuticals, Inc. to Present at the 2019 Biotech Showcase™ in San Francisco

2018-12-21 14:08:55 | How Does Investing In Actinium Pharmaceuticals, Inc. NYSEMKT:ATNM Impact The Volatility Of Your Portfolio?

2018-12-04 08:00:00 | Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting

2018-12-03 08:00:00 | Actinium Highlights Actimab-A Phase 2 Trial Results in Older Patients with Unfit AML from ASH Annual Meeting Demonstrating Single Agent Activity of the CD33 Antibody Radiation Conjugate